The Moderate to Severe COPD Trial

About this trial

Chronic obstructive pulmonary disease (COPD) is a progressive lung condition that causes the airways to narrow over time, making breathing increasingly difficult. It is a chronic disease, meaning there is currently no cure, but with the right treatments, many people with COPD continue to live long and fulfilling lives. Symptoms can be mild in the early stages and are sometimes mistaken for asthma, low fitness, or simply getting older. When symptoms do appear, they may include shortness of breath, recurring cough, phlegm or mucus, fatigue, and more frequent chest infections with longer recovery times.

COPD is the fifth leading cause of death and disease burden in Australia. About 1 in 13 people over the age of 40 are thought to have COPD, yet around 50% may not know they have it. In 2022, an estimated 496,000 Australians aged 45 and over were living with COPD, and in 2023–24 there were 69,200 hospitalisations where COPD was the principal diagnosis. Despite existing treatments helping to manage symptoms, there remains a continued need for more effective, safe, and accessible therapeutic options.

This trial is evaluating a new investigational treatment delivered by injection under the skin that may help improve outcomes for people living with moderate to severe COPD, offering a potential new option for those whose condition is not fully controlled by current therapies.